Skip to main content
. 2020 Jun 9;31(10):107745. doi: 10.1016/j.celrep.2020.107745

Figure 1.

Figure 1

Nuclear Antigen Recognized by the pSer137-Pfn1 Antibody Associates with Poor Survival Among Chemotherapy-Treated Breast Cancer Patients

(A) Representative images of the nuclear staining of human breast tumors by the pSer137-Pfn1 antibody. 20X magnification; scale bars, 100 μm.

(B–D) Univariate Kaplan-Meier analyses showing an inverse correlation between nuclear staining by the pSer137-Pfn1 antibody and patient survival in the SPECS series (B), UBC series (C), and the TNBC subset of the UBC series (D). OS, overall survival; RFS, relapse-free survival; BCSS, breast cancer-specific survival; TNBC, triple-negative breast cancer.

(E) Univariate Kaplan-Meier analysis of the BCCancer series showing the associations between nuclear staining by the pSer137-Pfn1 antibody and poor survival outcome (BCSS) of the chemotherapy-treated breast cancer patients. Log-rank and Wilcoxon tests were used. p < 0.05 was considered statistically significant. Unadjusted p values for the outcome in the chemotherapy-treated group of BCCancer series are displayed.

See also Figures S1–S3 and Tables S1–S9.